, pub-5475981771945671, DIRECT, f08c47fec0942fa0

GenScript ProBio, Abogen Biosciences and Walvax Biotechnology Deal on mRNA Vaccine

GenScript ProBio, Abogen Biosciences and Walvax Biotechnology Deal on mRNA Vaccine

NANJING, China and SINGAPORE/2021 /PRNewswire/ — GenScript ProBio, Suzhou Abogen Biosciences Technology Co. and Walvax Biotechnology Co. announced a collaboration on commercial manufacturing of an mRNA vaccine project (“ABO-028M”). Walvax Biotechnology will submit a BLA of the ABO-028M project and GenScript ProBio will provide exclusive services for the commercial manufacturing of plasmids in the project.

In June 2020, the COVID-19 mRNA vaccine project that Abogen Biosciences engaged with the Academy of Military Medical Sciences (AMMS) of the PLA Academy of Military Science and Walvax Biotechnology successfully obtained the NMPA clinical trial approval. It was one of the first batches of mRNA vaccine projects approved by the government of China. GenScript ProBio, with the advantage of the plasmid GMP manufacturing platform and rich experiences in plasmid clinical manufacturing, contributed to accelerating the pace of the mRNA vaccine project into a clinical trial. The project is currently undergoing international multicenter clinical trials and has obtained Phase III clinical trial approvals from the medical products regulatory authorities of Mexico, Indonesia and Nepal. In September 2021, Walvax Biotechnology’s modular facilities for COVID-19 mRNA vaccine was put into operation to accelerate the industrial manufacturing of COVID-19 vaccine.

Three parties have reached collaboration with complementary advantages to achieve mutual benefits on mRNA vaccine and drive the commercialization of the COVID-19 mRNA vaccine project of Abogen Biosciences and Walvax Biotechnology.

“It is a pleasure to collaborate with GenScript ProBio, a partner with highly professional platforms. It has a leading plasmid GMP manufacturing platform in China that provides in vitro transcription template linearized plasmids for mRNA vaccines. It’s robust manufacturing process will accelerate the commercialization of our COVID-19 mRNA vaccine and help to fight the pandemic,” said Dr. Ying Bo, founder and CEO of Abogen Biosciences.

“Walvax Biotechnology will work with our partners to proceed with the license application for clinical and emergency use of the COVID-19 mRNA vaccine and contribute to the containment of global pandemic and development of public health around the world. Let’s look forward to further progress of the project,” said Mr. Huang Zhen, Vice Chairman of Walvax Biotechnology.

“The pandemic is still raging. Abogen Biosciences had launched the project since the very beginning of the outbreak of COVID-19. It is one of the first batches of mRNA vaccine projects approved by the government of China. We are very proud to provide support for such a meaningful project. We believe that with our high-quality and experienced plasmid manufacturing platform and joint efforts with our partners, we will be able to bring the COVID-19 mRNA vaccine to market sooner and thus contribute to the global fight against the pandemic,” said Dr Brian Min, CEO of GenScript ProBio.